Resultados da busca - Tudor‐Eliade Ciuleanu

Refinar Resultados
  1. 1
    XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

    XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small... por U. Gatzemeier, Tudor‐Eliade Ciuleanu, Mircea Dediu, Elena Ganea‐Motan, Heinz Lubenau, Auro del Giglio

    Publicado em 2009
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  2. 2
    First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

    First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study por J.-Y. Douillard, Gyula Ostoros, Manuel Cobo, Tudor‐Eliade Ciuleanu, R. McCormack, Alan Webster, Tsveta Milenkova

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous Iron in patients with chemotherapy‐induced anemia

    Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous Iron in patients with chemotherapy‐induced anemia por Michael Auerbach, Peter T. Silberstein, R. Timothy Webb, S. V. Averyanova, Tudor‐Eliade Ciuleanu, James Shao, Kenneth R. Bridges

    Publicado em 2010
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy

    Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy por Bruno Coudert, Tudor‐Eliade Ciuleanu, K. Park, Yi‐Long Wu, Giuseppe Giaccone, Wolfram Brugger, P. Gopalakrishna, Federico Cappuzzo

    Publicado em 2011
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

    Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blin... por Robert E. Smith, Matti Aapro, Heinz Ludwig, Tamás Pintér, Martin Šmakal, Tudor‐Eliade Ciuleanu, Li Chen, Tom Lillie, John A. Glaspy

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

    Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer por Mary O’Brien, Tudor‐Eliade Ciuleanu, H. Tsekov, Yaroslav Shparyk, Branka Čučeviá, Gábor Juhász, Nicholas Thatcher, Graham Ross, G. Dane, T. Crofts

    Publicado em 2006
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

    A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed On... por John D. Hainsworth, C. Cebotaru, Vladimir Kanarev, Tudor‐Eliade Ciuleanu, Danail Damyanov, Phillip J. Stella, Hristo Ganchev, G. Pover, Clive Morris, Valentina Tzekova

    Publicado em 2010
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

    Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanc... por J.M. del Campo, A. Roszak, Mariusz Bidziński, Tudor–Eliade Ciuleanu, Thomas Högberg, Marek Z. Wojtukiewicz, Andrés Poveda, Karin Boman, Anneke M. Westermann, Claudia Lebedinsky

    Publicado em 2009
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

    FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECO... por Thomas Brodowicz, Tudor–Eliade Ciuleanu, Davorin Radosavljević, Einat Shacham‐Shmueli, D. Vrbanec, Signe Plāte, Zrinka Mršić-Krmpotić, Magdolna Dank, Gunta Purkalne, Diethelm Messinger, Christoph Zielinski

    Publicado em 2013
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

    Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status por Jean‐Yves Douillard, Gyula Ostoros, Manuel Cobo, Tudor‐Eliade Ciuleanu, Rebecca Cole, Gael McWalter, Jill Walker, Simon Dearden, Alan Webster, Tsveta Milenkova, Rose McCormack

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  11. 11
    Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations

    Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations por Barbara Klughammer, Wolfram Brugger, Federico Cappuzzo, Tudor‐Eliade Ciuleanu, Tony Mok, Martin Reck, Eng Huat Tan, Paul Delmar, Gaëlle Klingelschmitt, Anny-Yue Yin, Olivia Spleiss, Lin Wu, David S. Shames

    Publicado em 2016
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  12. 12
    Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation

    Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomiz... por George Fountzilas, E. Ciuleanu, Mattheos Bobos, Anna Kalogera‐Fountzila, Anastasia G Eleftheraki, Georgia Karayannopoulou, T. Zaramboukas, Angelos Nikolaou, Konstantinos Markou, Liliana Resiga, Dimitrios Dionysopoulos, E. Samantas, H. Athanassiou, D. Misailidou, Dimostenis Skarlos, Tudor‐Eliade Ciuleanu

    Publicado em 2011
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  13. 13
    Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)

    Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergro... por C. Le Péchoux, A. Laplanche, Corinne Faivre‐Finn, Tudor‐Eliade Ciuleanu, Rinus Wanders, D. Lerouge, Ronald B. Keus, M. Hatton, G. Videtic, Suresh Senan, Aaron H. Wolfson, Robert J. Jones, R. Arriagada, Élisabeth Quoix, Ariane Dunant

    Publicado em 2010
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  14. 14
    Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

    Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer por Marc Peeters, Timothy Price, Andrés Cervantes, Alberto Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, A. H. Strickland, G. Wilson, Tudor‐Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Yong‐Sheng Tian, R. Sidhu

    Publicado em 2013
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  15. 15
    Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

    Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metast... por Radka Obermannová, Eric Van Cutsem, Takayuki Yoshino, G. Bodoky, Jana Prausová, Rocio García‐Carbonero, Tudor‐Eliade Ciuleanu, Pilar Alfonso, David C. Portnoy, Allen Lee Cohn, Kentaro Yamazaki, P. Clingan, Sara Lonardi, Tae‐Woo Kim, Lifen Yang, Federico Nasroulah, Josep Tabernero

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA

    OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Ce... por Martin Reck, Tudor‐Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Żurawski, J. Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Óscar Juan, Aurelia Alexandru, Hiroshi Sakai, Arnaud Scherpereel, Shun Lu, Thomas John, David P. Carbone, S. Meadows–Shropshire, Jiarui Yan, Luis Paz‐Ares

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  17. 17
    Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

    Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Che... por Corey J. Langer, Kenneth J. O’Byrne, Mark A. Socinski, С. М. Михайлов, Krzysztof Leśniewski-Kmak, Martin Šmakal, Tudor‐Eliade Ciuleanu, С. В. Орлов, Mircea Dediu, David F. Heigener, Amy J. Eisenfeld, Larissa Sandalic, F. B. Oldham, Jack W. Singer, Helen J. Ross

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  18. 18
    Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

    Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial por Janja Ocvirk, Thomas Brodowicz, Fritz Wrba, Tudor‐Eliade Ciuleanu, G. Kurteva, S. Beslija, I Koza, Zsuzsanna Pápai, Diethelm Messinger, Uğur Yılmaz, Zsolt Faluhelyi, Şuayib Yalçın, Demetris Papamichael, M. Wenczl, Zrinka Mršić-Krmpotić, Einat Shacham‐Shmueli, Damir Vrbanec, Regina Esser, Werner Scheithauer, Christoph Zielinski

    Publicado em 2010
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  19. 19
    Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

    Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer por Mark A. Socinski, Egbert F. Smit, Paul Lorigan, Kartik Konduri, Martin Reck, Aleksandra Szczęsna, Johnetta Blakely, Piotr Serwatowski, Nina Karaseva, Tudor‐Eliade Ciuleanu, Jacek Jassem, Mircea Dediu, Shengyan Hong, Carla Visseren‐Grul, Axel-Rainer Hanauske, Coleman K. Obasaju, Susan C. Guba, Nick Thatcher

    Publicado em 2009
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  20. 20
    International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1

    International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cance... por Giorgio V. Scagliotti, Ihor Vynnychenko, Keunchil Park, Yukito Ichinose, Kaoru Kubota, Fiona Blackhall, Robert Pirker, Rinat Galiulin, Tudor‐Eliade Ciuleanu, Oleksandr Sydorenko, Mircea Dediu, Zsolt Pápai-Székely, Natividad Martínez-Banaclocha, Sheryl McCoy, Bin Yao, Yong‐jiang Hei, Francesco Galimi, David R. Spigel

    Publicado em 2012
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: